CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 17 enrolled / 17 target
Drug / intervention
Guselkumabdrug
Likely dose
Guselkumab 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04645355
NCT04645355Phase 4CompletedUpdate Overdue (0.3/mo)Completion was 14mo ago
CompareCT.gov

Immunogenetic Profiling of Guselkumab for the Treatment of Plaque and Guttate Psoriasis

University of California, San Francisco·interventional·Posted Nov 27, 2020·Updated Jun 23, 2026

In Brief

A Phase 4 clinical trial evaluating Guselkumab for Psoriasis Guttate and Plaque Psoriasis. Completed, enrolled 17 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Guttate, Plaque Psoriasis
CountriesUnited States
CollaboratorsJanssen Biotech, Inc.

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedNov 27, 2020
Enrollment StartMar 1, 2021
Primary CompletionApr 4, 2025
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 5.6 years ago

Arms & Interventions

New-onset guttate psoriasisexperimental

Subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44. At week 44, patients who have not achieved PASI 50 (nonresponders) will be removed from the trial. Patients who achieve between PASI 50 and PASI 75 (partial responders) will continue on drug throughout the remainder of the study. Patients who achieve PASI 75 or greater at week 44 (responders) will have their guselkumab therapy withdrawn and re-treated upon relapse.

Drug: Guselkumab
Chronic plaque psoriasisexperimental

Subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44. At week 44, patients who have not achieved PASI 50 (nonresponders) will be removed from the trial. Patients who achieve between PASI 50 and PASI 75 (partial responders) will continue on drug throughout the remainder of the study. Patients who achieve PASI 75 or greater at week 44 (responders) will have their guselkumab therapy withdrawn and re-treated upon relapse.

Drug: Guselkumab

Interventions

Guselkumabdrug

All subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44